Key facts
- CuraSen’s last known valuation is $119.4M (Sep 2024).
- It has raised $106.8M; the latest was Later Stage VC ($10.9M) in Jul 2025.
- Notable investors include Johnson & Johnson JJDC, Longitude Capital, New Leaf Venture, ABRDN Emerging Markets Equity Income, Alta Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CuraSen
- ·The full record, as it builds
Funding rounds
No funding rounds for CuraSen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CuraSen
Operator of a biopharmaceutical company intended for the development of novel treatments for neurodegenerative diseases. The company engages in developing small molecules that target innate homeostatic pathways and develops drugs for neurodegenerative disorders like inflammation, proteinopathy, neuronal atrophy, Alzheimer's, and Parkinson's diseases, enabling healthcare professionals to effectively treat patients with neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2013
- Employees
- 20
- Website
- curasen.com/
- Ownership
- Privately Held (backing)
CuraSen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CuraSen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CuraSen in its N-PORT filings yet. We sweep new filings monthly.